Q1 EPS Estimates for Astrana Health Lowered by William Blair

Astrana Health, Inc. (NASDAQ:ASTH - Free Report) - Investment analysts at William Blair dropped their Q1 2025 earnings per share estimates for Astrana Health in a research note issued to investors on Thursday, February 27th. William Blair analyst R. Daniels now anticipates that the company will earn $0.21 per share for the quarter, down from their previous forecast of $0.29. The consensus estimate for Astrana Health's current full-year earnings is $1.15 per share. William Blair also issued estimates for Astrana Health's Q2 2025 earnings at $0.34 EPS, Q3 2025 earnings at $0.43 EPS, Q4 2025 earnings at $0.37 EPS and FY2025 earnings at $1.34 EPS.

Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.37). The firm had revenue of $665.21 million during the quarter, compared to analysts' expectations of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%.

Several other analysts have also issued reports on ASTH. Stifel Nicolaus cut their target price on Astrana Health from $70.00 to $56.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Bank of America dropped their price objective on Astrana Health from $55.00 to $49.00 and set a "buy" rating for the company in a research note on Tuesday. Truist Financial dropped their price objective on Astrana Health from $59.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, January 13th. Macquarie raised Astrana Health to a "hold" rating in a research note on Monday, December 16th. Finally, Robert W. Baird dropped their price objective on Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a research note on Monday. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.83.

Remove Ads

Astrana Health Price Performance

ASTH traded up $0.02 during midday trading on Monday, hitting $27.21. The stock had a trading volume of 242,543 shares, compared to its average volume of 244,744. The company has a market cap of $1.53 billion, a P/E ratio of 20.93, a price-to-earnings-growth ratio of 1.37 and a beta of 1.20. The business has a fifty day moving average of $34.44 and a 200 day moving average of $44.05. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. Astrana Health has a 1 year low of $23.12 and a 1 year high of $63.20.

Hedge Funds Weigh In On Astrana Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. PharVision Advisers LLC bought a new position in shares of Astrana Health during the fourth quarter valued at approximately $211,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Astrana Health by 15.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,658 shares of the company's stock valued at $3,300,000 after acquiring an additional 14,138 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Astrana Health during the fourth quarter valued at approximately $1,208,000. Two Sigma Investments LP bought a new position in shares of Astrana Health during the fourth quarter valued at approximately $466,000. Finally, Sherbrooke Park Advisers LLC bought a new position in shares of Astrana Health during the fourth quarter valued at approximately $494,000. Institutional investors own 52.77% of the company's stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.